Master Collaboration Agreement Sample Contracts

Share Cite Term
Link

Embed (HTML)
Bluebird Bio Inc. – Amendment No. 2 to Amended and Restated Master Collaboration Agreement (November 1st, 2017)

This Amendment No. 2 to Amended and Restated Master Collaboration Agreement (this "Amendment No. 2") is made as of September 28, 2017 ("Amendment No. 2 Effective Date"), by and between bluebird bio, Inc. ("Bluebird"), a Delaware corporation, and Celgene Corporation, a Delaware corporation ("Celgene Corp."), and Celgene European Investment Company LLC ("Celgene Europe"), a Delaware limited liability company (Celgene Europe and Celgene Corp., together, "Celgene"). Each of Bluebird and Celgene may be referred to herein as a "Party" or together as the "Parties". Reference is hereby made to that certain Amended and Restated Master Collaboration Agreement, by and between Bluebird, Celgene Corp. and Celgene Europe, dated June 3, 2015, as amended (the "Agreement"). Capitalized terms used but not otherwise defined herein shall have the meanings given to such terms in the Agreement.

Master Collaboration Agreement (November 10th, 2016)

Blueprint is a global pharmaceutical company engaged in the research, development, manufacture and commercialization of pharmaceutical products to treat disease;

Master Collaboration Agreement (July 22nd, 2016)

This Master Collaboration Agreement (this "Agreement") is effective March 1, 2016, (the "Effective Date"), by and between Ventana Medical Systems, Inc., a Delaware corporation with offices located at 1910 E. Innovation Park Drive, Tucson, AZ 85755 USA ("Ventana"), and Blueprint Medicines Corporation, a Delaware corporation with offices located at 38 Sidney Street, Suite 200, Cambridge, MA 02139 USA ("Blueprint").

Master Collaboration Agreement (May 10th, 2016)

This Master Collaboration Agreement (this "Agreement") is effective March 1, 2016, (the "Effective Date"), by and between Ventana Medical Systems, Inc., a Delaware corporation with offices located at 1910 E. Innovation Park Drive, Tucson, AZ 85755 USA ("Ventana"), and Blueprint Medicines Corporation, a Delaware corporation with offices located at 38 Sidney Street, Suite 200, Cambridge, MA 02139 USA ("Blueprint").

Amendment No. 1 to Master Collaboration Agreement (November 9th, 2015)

This First Amendment (this Amendment), effective as of the date of the last signature set forth below (the Amendment Effective Date), amends that certain Master Collaboration Agreement dated January 11, 2014 (the Master Agreement), and certain of the License Terms attached thereto, by and between Alnylam Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware (Alnylam), and Genzyme Corporation, a corporation organized and existing under the laws of the Commonwealth of Massachusetts (Genzyme). The Master Agreement, together with the License Terms attached thereto, are referred to collectively herein as the Collaboration Agreement. Alnylam and Genzyme are individually referred to herein as a Party and collectively referred to as the Parties.

Tokai Pharmaceuticals Inc – Confidential Materials Omitted and Filed Separately With the Securities and Exchange Commission. Double Asterisks Denote Omissions. Companion Diagnostics MASTER COLLABORATION AGREEMENT (May 12th, 2015)
MASTER COLLABORATION AGREEMENT by and Between ALNYLAM PHARMACEUTICALS, INC. And GENZYME CORPORATION (May 9th, 2014)

THIS MASTER COLLABORATION AGREEMENT (this Master Agreement), entered into as of January 11, 2014 (the Execution Date), is entered into by and between Alnylam Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware (Alnylam), and, Genzyme Corporation, a corporation organized and existing under the laws of the Commonwealth of Massachusetts (Genzyme).

Bluebird Bio Inc. – Contract (May 21st, 2013)

CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

Bluebird Bio Inc. – Contract (May 14th, 2013)

CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

KL Energy Corp – Master Collaboration Agreement (October 5th, 2010)

This Master Collaboration Agreement ("Agreement") is made as of August 30, 2010 (the "Effective Date"), by and between KL Energy Corporation, a Nevada corporation with offices at 306 East St. Joseph Street, Suite 200, Rapid City, South Dakota 57701 (the "Company"), and add blue Consultoria Ltda., a company organized in Brazil with offices at Rua Joaquim Nabuco, 47, office 81, Brooklin, City of Sao Paulo, State of Sao Paulo, 04621-000 ("Add Blue").